#vleadersLifeScience 2017: Meet Patrizia Marschalkovà from Dicronis
10.05.2017
Leaving to Boston on June 11 until June 17, this year’s venture leaders Life Science forming the ‘Swiss National Startup Team Life Science 2017’ reflect the impressive quality of Swiss startups, whose innovations come from the best universities and research institutes of Switzerland. Learn more about their growth objectives before the trip in our short interview series, running from May 9 to May 22 on venturelab.ch, Facebook, Twitter and LinkedIn.
 Patrizia Marschalkova from Dicronis (Medtech, ETHZ)
|
 |
You can see the whole campaign on twitter.com/venturelab_ch searching the hashtag #vleadersLifeScience.
Lymphedema is a frequently occurring and serious complication of cancer therapies. Dicronis helps to drastically improve its prognosis thanks to a simple, safe, minimally-invasive and cost-effective technology based on micr-needles.
Why do you choose Boston as your business development destination?
Boston, with its vibrant startup ecosystem and inclination for innovation, will allow me to explore new opportunities for my company. With this trip, I can grasp the approach of young Americans towards entrepreneurship, and this in their environment. I am also very curious about what startups are doing there, in particular in the pharma/biotech field. Furthermore, I will have the time to evaluate whether Boston is a valid location for subsidiaries of Dicronis in the USA, once the company will have grown.
What do you want to achieve from the trip?
At the current status of Dicronis, the most important element that I can bring home is how our first product in the pipeline, Lymphit, is perceived overseas, either from investors or other entrepreneurs. This will have an important impact in its development and how we will conceive the future products. The US market is primary for the growth of our company, and I aim to establish concrete contacts with players in different fields: doctors, lawyers, health insurances executives, investors, entrepreneurs in the same field and possibly future partners. Getting a feedback from regulatory affairs personnel will be instrumental in the planning of the clinical studies, as the US Food and Drug Administration (FDA) is the most up-to-date regulatory competent authority. Not less important is to get an insight on how people in our field communicate or connect in the US. From my side, I will do my best to share my entrepreneurial experience with US peers and offer them insights about the Swiss startup environment.
Why is venture leaders Life Science really beneficial for your company?
venture leaders Life Science gives invaluable visibility to Dicronis, both locally and internationally. After an entire week together, the program gives the opportunity to establish a bond between the participants, which I am sure will bring value in different ways for the respective startups. Finally, having the opportunity to interact with like-minded innovators and a little “crazy” entrepreneurs is the part that I enjoy the most of my job.